ECG
Everus Construction Group, Inc.
ECG has the edge over RDW overall, supported by lower modeled downside and stronger valuation.
RDW
Redwire Corporation
RDW's outlook is improving, though it still trails on the overall score.
ECG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
ECG's revenue, profitability, cash flow and balance sheet are all currently healthy.
RDW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RDW's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ECG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $87.17 | — |
| Current | 15x | $87.17 | — |
| Cheap | 20x | $113 | +29% |
| Fair | 25x | $142 | +63% |
| Expensive | 31x | $174 | +100% |
Historical ranges are pointers, not guarantees.
ECG's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
RDW PE Valuation
RDW has no meaningful PE right now: it lost money over the past year.
ECG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ECG, with profitability improving. However, they disagree widely on these estimates.
RDW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect RDW's losses to shrink, with revenue growing.
ECG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.78 | +20% |
| Q3 2026 | $5.66 | +60% |
| Q2 2026 | $4.98 | +53% |
| Q1 2026 | $4.37 | +47% |
| Q4 2025 | $3.95 | +35% |
| Q3 2025 | $3.54 | +37% |
| Q2 2025 | $3.25 | +31% |
| Q1 2025 | $2.98 | +20% |
| Q4 2024 | $2.92 | +19% |
ECG has the edge over RDW on earnings quality, reporting a profit while its opponent remains loss making.
RDW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.17 | +$2.01 |
| Q2 2026 | -$1.37 | +$1.89 |
| Q1 2026 | -$2.59 | -$0.32 |
| Q4 2025 | -$2.28 | +$0.07 |
| Q3 2025 | -$3.18 | -$1.97 |
| Q2 2025 | -$3.26 | -$2.28 |
| Q1 2025 | -$2.27 | -$1.55 |
| Q4 2024 | -$2.35 | -$1.62 |
RDW is still losing money, but far less than before: $1.17 per share over the past year, against $3.26 at its worst in mid-2025.
ECG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +40% |
| Q2 2026 | $1.2B | +34% |
| Q1 2026 | $1B | +25% |
| Q4 2025 | $1B | +33% |
| Q3 2025 | $986.8M | +30% |
| Q2 2025 | $921.5M | +31% |
| Q1 2025 | $826.6M | +32% |
| Q4 2024 | $759.6M | +19% |
ECG has the edge over RDW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.8% | +1.5 points |
| Q2 2026 | 9.1% | +1.2 points |
| Q1 2026 | 7.5% | +1.3 points |
| Q4 2025 | 6.8% | +0.8 points |
| Q3 2025 | 7.3% | +0.3 points |
| Q2 2025 | 7.9% | +0.6 points |
| Q1 2025 | 6.2% | 0 points |
| Q4 2024 | 6.1% | -2 points |
ECG has the edge over RDW on profitability, with a higher operating margin.
RDW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $109M | +5.4% |
| Q2 2026 | $117.1M | +90% |
| Q1 2026 | $97M | +58% |
| Q4 2025 | $108.8M | +56% |
| Q3 2025 | $103.4M | +51% |
| Q2 2025 | $61.8M | -21% |
| Q1 2025 | $61.4M | -30% |
| Q4 2024 | $69.6M | +9.6% |
RDW's revenue has grown year over year for five quarters in a row: $109M last quarter, up 5.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +16 points |
| Q2 2026 | -19% | +130 points |
| Q1 2026 | -72% | -49 points |
| Q4 2025 | -75% | -48 points |
| Q3 2025 | -40% | -22 points |
| Q2 2025 | -149% | -140 points |
| Q1 2025 | -23% | -19 points |
| Q4 2024 | -27% | -17 points |
RDW's operating margin was −24% last quarter, up 16 points from the same quarter a year ago.
ECG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.7M | -20% |
| Q2 2026 | $33M | +169% |
| Q1 2026 | $128.2M | +$139.6M |
| Q4 2025 | $23.5M | -65% |
| Q2 2025 | $12.3M | +$37.7M |
| Q1 2025 | -$11.4M | -190% |
| Q4 2024 | $66.9M | -35% |
| Q2 2024 | -$25.4M | -$6M |
ECG has the edge over RDW on cash generation, producing positive trailing cash flow while its opponent burns cash.
RDW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.3M | -$38.5M |
| Q2 2026 | -$33.5M | +$57.2M |
| Q1 2026 | -$11.4M | +$35.5M |
| Q4 2025 | -$26.5M | -659% |
| Q3 2025 | -$26.9M | -$7.6M |
| Q2 2025 | -$90.6M | -$80.2M |
| Q1 2025 | -$46.9M | -3996% |
| Q4 2024 | $4.7M | -65% |
RDW has burned cash in most quarters: −$137M over the past year, against −$160M the year before.
ECG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +19K shares |
| 1 year | +0.2% | +102K shares |
| 3 years | +0.5% | +267K shares |
ECG has the edge over RDW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
RDW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +29.6M shares |
| 1 year | +179% | +160M shares |
| 3 years | +289% | +186M shares |
| 5 years | +319% | +190M shares |
RDW has 250M diluted shares, up 179% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ECG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2024 | 1.5x | Healthy |
| Q1 2024 | 0.0x | Very low |
| Q4 2023 | 0.9x | Very low |
ECG's net debt is less than a year of its operating earnings (EBITDA).
RDW Net Leverage
RDW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ECG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 15.6 | Oversold |
ECG's weekly RSI is 36 (neutral) and its Stochastic is 16 (oversold).
RDW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 16.1 | Oversold |
RDW's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
ECG PE vs Industrials Sector
| Metric | ECG | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 24x | 36% below |
| PE % | 9 | 31 | 22 pts below |
ECG is trading at 15x earnings, a 36% discount to the Industrials sector's median of 24x.
RDW PE vs Industrials Sector
RDW has no meaningful PE right now: it lost money over the past year.
ECG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.2 | 16% below |
| 20 week MA | $118.5 | 26% below |
| 50 week MA | $119.1 | 27% below |
| 100 week MA | $92.3 | 5.5% below |
RDW has stronger trend alignment. ECG is above 0 of 4 weekly averages versus RDW above 0 of 5.
RDW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.06 | 11% below |
| 20 week MA | $10.1 | 20% below |
| 50 week MA | $10.6 | 24% below |
| 100 week MA | $11.6 | 31% below |
| 200 week MA | $8.07 | 0.5% below |
RDW is in a downtrend: it's below all five of its weekly moving averages, and 0.5% below its 200-week average.
ECG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $52.5 | $69.9 | +33% |
| 2025 | $69.9 | $90.1 | +29% |
| 2026 YTD | $90.1 | $87.2 | -3.2% |
ECG has finished every year since 2024 higher, and it's down 3.2% so far in 2026.
RDW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.2 | $7.34 | -28% |
| 2022 | $7.34 | $1.92 | -74% |
| 2023 | $1.92 | $2.85 | +48% |
| 2024 | $2.85 | $17.1 | +501% |
| 2025 | $17.1 | $7.15 | -58% |
| 2026 YTD | $7.15 | $8.03 | +12% |
RDW has the edge over ECG on returns for 2026, with the stronger performance.